How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). During the same period in the previous year, the company earned ($0.24) EPS.

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX) , VBI Vaccines (VBIV) , Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Kadmon (KDMN) , Matinas BioPharma (MTNB) , Cidara Therapeutics (CDTX) , ADMA Biologics (ADMA) , DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX) .

When did Aptinyx IPO?

Aptinyx (APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

NASDAQ:APTX

Aptinyx (APTX) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free APTX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.09
▼
$0.10
50-Day Range: $0.06
▼
$0.10
52-Week Range: $0.01
▼
$0.72

Volume: 231,100 shs
Average Volume: 1.32 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Earnings Insider Trades Ownership Social Media

Get Aptinyx alerts:

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Aptinyx Stock (NASDAQ:APTX)

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Protect your retirement savings from the inevitable devaluation of the dollar…

APTX Stock News Headlines

March 12, 2024 | benzinga.com

New Leaf Venture Management III, L.L.C.'s Net Worth

February 9, 2024 | benzinga.com

Patrick J Heron's Net Worth

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

January 13, 2024 | cnet.com

Best Noise-Canceling Headphones for 2024

December 17, 2023 | morningstar.com

Aptinyx Inc APTX

September 7, 2023 | morningstar.com

North American Morning Briefing: Concerns About -2-

March 30, 2023 | finance.yahoo.com

Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now

February 27, 2023 | finance.yahoo.com

Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

January 31, 2023 | finance.yahoo.com

Aptinyx to Present at the SVB Securities Global Biopharma Conference

January 16, 2023 | ca.finance.yahoo.com

Aptinyx Inc. (APTX) Stock Historical Prices & Data - Yahoo Finance

January 5, 2023 | fool.com

Aptinyx (NASDAQ: APTX)

December 30, 2022 | insidermonkey.com

Aptinyx Inc. (NASDAQ:APTX) Q3 2022 Earnings Call Transcript

December 12, 2022 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)

November 8, 2022 | finance.yahoo.com

Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

October 30, 2022 | fool.com

Aptinyx Inc. (NASDAQ: APTX)

October 18, 2022 | finance.yahoo.com

Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 2, 2022 | reuters.com

APTX.OQ - Aptinyx Inc | Stock Price & Latest News | Reuters

September 24, 2022 | finance.yahoo.com

Aptinyx Inc. (APTX)

September 12, 2022 | nasdaq.com

Hopeful week for insiders who might be regretting buying US$567k of Aptinyx Inc. (NASDAQ:APTX) stock earlier this year - Nasdaq

August 26, 2022 | marketscreener.com

HC Wainwright Adjusts Price Target on Aptinyx to $1 From $2, Reiterates Buy Rating - Marketscreener.com

August 25, 2022 | businesswire.com

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies - Business Wire

August 25, 2022 | finance.yahoo.com

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

August 22, 2022 | finance.yahoo.com

Bullish Aptinyx Inc. (NASDAQ:APTX) investors are yet to receive a pay off on their US$567k bet

August 19, 2022 | nasdaq.com

Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates - Nasdaq

August 17, 2022 | morningstar.com

North American Morning Briefing: Investors Seek -2- - Morningstar

August 16, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Aptinyx

See More Headlines

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:APTX
CUSIP: N/A
CIK: 1674365
Web: www.aptinyx.com
Phone: (847) 871-0377
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $1 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.57 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.27

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Craig R. Jalbert CIRA (Age 61)
Principal Executive Officer, Fin. & Accounting Officer, President, Treasurer, Secretary and Director
Mr. Patrick Flavin
Senior Manager of Corporate Development & Investor Relations
Ms. Molly Dir
Vice President of Human Resources
Dr. Kathryn King Ph.D.
Senior Vice President of Clinical & CMC Operations
Mr. Tim Noffke
VP of Program Management & Chief of Staff
Dr. Harald Murck M.D.
Ph.D., Vice President of Clinical & Medical Affairs

Key Competitors

View All Competitors

APTX Stock Analysis - Frequently Asked Questions

How were Aptinyx's earnings last quarter?: Aptinyx Inc. (NASDAQ:APTX) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). During the same period in the previous year, the company earned ($0.24) EPS.
What other stocks do shareholders of Aptinyx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX).
When did Aptinyx IPO?: Aptinyx (APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

This page (NASDAQ:APTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aptinyx (APTX) Stock Price, News & Analysis

About Aptinyx Stock (NASDAQ:APTX)

APTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

APTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info